A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

被引：5
|
作者：
Faulkner, Neil
LoRusso, Patricia M.
Guthrie, Tina
Soria, Jean-Charles
Bahleda, Ratislav
Bendell, Johanna C.
Infante, Jeffrey R.
Massard, Christophe
Van Leeuwen, Barbara
Martini, Jean-Francois
Scheffold, Christian
Burns, Howard A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163,TARG-09-C197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C197
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
    Moldovan, C.
    Soria, J.
    LoRusso, P.
    Guthrie, T.
    Song, C.
    Nguyen, L. T.
    Martini, J.
    Infante, J. R.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors
    Wheler, Jennifer J.
    Traynor, Anne M.
    Bailey, Howard H.
    Alta, Steven
    Falchook, Gerald S.
    Laird, A. Douglas
    Linh Nguyen
    Scheffold, Christian
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [3] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
    Traynor, A. M.
    Kurzrock, R.
    Bailey, H. H.
    Attia, S.
    Scheffold, C.
    van Leeuwen, B.
    Wu, B.
    Falchook, G. S.
    Moulder, S. L.
    Wheler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Shapiro, Geoffrey I.
    Rodon, Jordi
    Bedell, Cynthia
    Kwak, Eunice L.
    Baselga, Jose
    Brana, Irene
    Pandya, Shuchi S.
    Scheffold, Christian
    Laird, A. Douglas
    Nguyen, Linh T.
    Xu, Yi
    Egile, Coumaran
    Edelman, Gerald
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 233 - 245
  • [5] Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
    Matulonis, Ursula
    Vergote, Ignace
    Backes, Floor
    Martin, Lainie P.
    McMeekin, Scott
    Birrer, Michael
    Campana, Frank
    Xu, Yi
    Egile, Coumaran
    Ghamande, Sharad
    GYNECOLOGIC ONCOLOGY, 2015, 136 (02) : 246 - 253
  • [6] Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in CombinationWith Erlotinib in Patients With Solid Tumors
    Soria, Jean-Charles
    LoRusso, Patricia
    Bahleda, Ratislav
    Lager, Joanne
    Liu, Li
    Jiang, Jason
    Martini, Jean-Francois
    Mace, Sandrine
    Burris, Howard
    ONCOLOGIST, 2015, 20 (03): : 245 - 246
  • [7] A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies
    Edelman, G.
    Bedell, C.
    Shapiro, G.
    Pandya, S. S.
    Kwak, E. L.
    Scheffold, C.
    Nguyen, L. T.
    Laird, A.
    Baselga, J.
    Rodon, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)
    Rodon, Jordi
    Shapiro, G., I
    Bedell, C.
    Kwak, E. L.
    Baselga, J.
    Brana, I
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2192 - 2192
  • [9] Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
    Wheler, Jennifer
    Mutch, David
    Lager, Joanne
    Castell, Christelle
    Liu, Li
    Jiang, Jason
    Traynor, Anne M.
    ONCOLOGIST, 2017, 22 (04): : 377 - E37
  • [10] Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma.
    Bechter, Oliver Edgar
    Dumez, Herlinde
    Costermans, Jo
    Punie, Kevin
    Liu, Li
    Jiang, Jason
    Dedieu, Jean-Francois
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345